Asthma Exacerbation: The Severity Pyramid
Asthma exacerbation is a common CCS case testing your ability to rapidly assess severity, escalate care appropriately, manage acute bronchospasm, and plan discharge with stepwise controller therapy. Unlike COPD, asthma patients do not retain CO₂ chronically—so aggressive oxygen and albuterol are always safe. This guide walks you through the exact protocols from mild to life-threatening exacerbations.
Severity Classification: The Foundation
The National Asthma Education and Prevention Program (NAEPP) severity classification determines your management approach:
Mild Exacerbation
Clinical findings:
• Dyspnea only with activity (not at rest)
• Able to speak in full sentences
• Respiratory rate normal to mildly elevated (<30)
• No accessory muscle use at rest
• Peak flow 80-100% predicted
Management: Outpatient; albuterol q4-6h; systemic steroids (oral prednisone) × 5-7 days
Moderate Exacerbation
Clinical findings:
• Dyspnea at rest, unable to speak full sentences
• Respiratory rate 25-30
• Mild-moderate accessory muscle use
• Peak flow 50-80% predicted
• SpO₂ 91-95% on room air
Management: Emergency department observation or admission; continuous/frequent nebulizers; IV/oral steroids; consider magnesium sulfate if not responding quickly
Severe Exacerbation
Clinical findings:
• Severe dyspnea at rest, only 1-2 words at a time
• Respiratory rate >30
• Marked accessory muscle use, subcostal retractions
• Confusion or altered mental status
• Peak flow <50% predicted
• SpO₂ 90-91% or lower
Management: ICU, continuous nebulizers, IV steroids, magnesium sulfate, consider subcutaneous epinephrine or IV terbutaline
Life-Threatening (Respiratory Failure)
Red flags:
• Inability to speak (aphonia)
• Silent chest (no air movement)
• Altered mental status, drowsiness
• Severe hypoxia (SpO₂ <90%)
• Profound hypercapnia (CO₂ >42 mmHg on ABG)
• Peak flow <33% predicted or unable to perform
Management: ICU, intubation likely needed, aggressive bronchodilation, IV steroids, prepare for difficult airway
> Study Tip: The StudyCCS question bank includes 9+ asthma exacerbation cases across all severity levels—showing you the exact moment when a moderate exacerbation requires ICU admission and when you need to intubate. These cases highlight the subtle clinical findings that signal deterioration.
Peak Flow Measurement & Interpretation
Peak flow is a critical objective assessment on CCS—use it to track response to therapy:
Technique:
• Upright position, deep inspiration, forceful expiration into meter
• Best of three attempts (allow 1-2 minutes between attempts)
• Normal: 380-760 L/min (varies by age, height, sex)
Interpretation in exacerbation:
• >80% predicted = mild
• 50-80% predicted = moderate
• 25-50% predicted = severe
• <25% predicted = life-threatening (or unable to perform = life-threatening)
On CCS: Order peak flow on presentation and after bronchodilator therapy (albuterol); improvement indicates response.
Acute Bronchodilator Therapy
Albuterol: The Cornerstone
Nebulized albuterol:
• Mild exacerbation: 2.5-5 mg q4-6h
• Moderate: 2.5-5 mg q20-30min for first 1-2 hours, then q1-4h
• Severe: Continuous nebulizer 5-10 mg/hr or back-to-back treatments q15-20min
• Onset: 5-15 minutes; peak 30-60 minutes
Systemic beta-2 agonists (for life-threatening exacerbations not responding to nebulizers):
• Subcutaneous epinephrine: 0.3-0.5 mg IM/SC q15-20min (use 1:1000 solution)
• IV terbutaline: 0.25 mg slow IV; risk of tachycardia, arrhythmias (reserved for ICU)
Cautions:
• Monitor heart rate, EKG (tachycardia, arrhythmias possible)
• Hypokalemia and hypophosphatemia with high-dose beta-2 agonists
• Tremor, anxiety (reassure patient—expected side effect)
Anticholinergics: The Supporting Player
• Ipratropium (Atrovent): 0.5 mg nebulized q6h or combined with albuterol (DuoNeb)
• Synergistic benefit in acute asthma (unlike COPD where benefit is larger)
• Combination approach: Albuterol + ipratropium q30min for moderate-severe exacerbations
Corticosteroids: Speed Matters
Systemic steroids are essential—they reduce airway inflammation and prevent relapse:
• Preferred: Oral prednisone 40-60 mg daily × 5-7 days (simple taper not needed)
• If unable to take oral: Methylprednisolone 125 mg IV q6h × 24h, then switch to oral
• Duration: 5-7 days total; no prolonged taper needed for acute exacerbations
• Timing: Give immediately; earlier steroids = faster improvement
• Monitor: Hyperglycemia (check fingerstick glucose, especially in diabetics)
> Practice Alert: Systemic corticosteroids appear in nearly every CCS asthma exacerbation case. The StudyCCS question bank shows you the exact dosing for each severity level and common mistakes (under-dosing, prolonged tapering). This builds confidence in rapid steroid initiation on exam day.
Magnesium Sulfate: For Resistant Cases
Indicated in moderate-severe exacerbations not responding to initial albuterol/steroids or for severe exacerbations:
• Dose: 2 g IV over 20 minutes
• Mechanism: Smooth muscle relaxation, bronchodilation; works synergistically with beta-2 agonists
• Onset: 10-20 minutes
• Can repeat: Once in first hour if inadequate response
• Side effects: Mild hypotension, flushing, headache; usually well-tolerated
• Monitoring: Check magnesium level (therapeutic 2-4 mEq/L); monitor for hypermagnesemia in renal disease
Oxygen & ABG
Oxygen targets:
• Maintain SpO₂ ≥92-94% (higher than COPD exacerbation)
• Asthma patients do NOT chronically retain CO₂ → aggressive oxygen is safe
• Use non-rebreather mask if SpO₂ <90%
ABG interpretation:
• Normal CO₂ (35-45) during exacerbation = concerning → indicates severe obstruction, limited air movement
• Early exacerbation: Respiratory alkalosis (low CO₂, high pH) from hyperventilation
• Severe/life-threatening: Rising CO₂ (>42) with acidosis = respiratory failure (intubate threshold)
When to draw ABG:
• Life-threatening exacerbation
• Not responding to initial therapy after 1-2 hours
• Altered mental status
• Any SpO₂ <90%
Intubation & ICU Criteria
Intubate if:
• Altered mental status (fatigue, confusion)
• Severe hypoxia (SpO₂ <90%) despite oxygen
• Severe hypercapnia (CO₂ >42-45 mmHg) with respiratory acidosis
• Inability to speak
• Silent chest (no air movement)
• Peak flow <33% predicted
• Hemodynamic instability
Pre-intubation management:
• Position upright, maximize albuterol nebulization
• IV access, push steroids, consider magnesium sulfate + terbutaline infusion
• Prepare for difficult airway (severe obstruction may impede visualization)
Intubation drugs:
• Induction: Etomidate (0.2 mg/kg) or propofol (1-2 mg/kg); avoid histamine releasers (atracurium, mivacurium) and morphine
• Paralysis: Rocuronium 1.2 mg/kg; avoid succinylcholine (histamine release risk)
• Strategy: Awake fiberoptic may be safest if severe obstruction
Ventilator strategy post-intubation:
• Permissive hypercapnia acceptable (allows lower tidal volumes, reduced airway pressure)
• Start AC 10-12 breaths/min, TV 6-8 mL/kg IBW, prolonged expiration time (I:E ratio 1:3 or 1:4)
• Minimal PEEP; risk of auto-PEEP with obstruction
• Monitor peak pressures; if >45 cm H₂O, reduce rate or tidal volume
Step-Up Therapy & Controller Initiation
During admission, establish long-term control:
Based on Frequency of Symptoms
Step 1: Intermittent asthma (≤2 days/week):
• Albuterol PRN only
Step 2: Mild persistent (>2 days/week, ≤1 night/month):
• ICS inhaler (beclomethasone 40-80 mcg BID, fluticasone 44-110 mcg BID)
Step 3: Moderate persistent (daily symptoms, ≥4 nights/month):
• ICS + long-acting beta-2 agonist (LABA): Fluticasone/salmeterol or budesonide/formoterol
• OR increase ICS dose
Step 4: Severe persistent (continual daytime, frequent nocturnal):
• High-dose ICS/LABA
Step 5-6: Refractory asthma:
• Add long-acting muscarinic antagonist (LAMA): Tiotropium inhaled 2.5 mcg daily
• Consider biologic: Omalizumab (IgE monoclonal), dupilumab (IL-4 receptor), mepolizumab (IL-5 monoclonal)
> Study Tip: The StudyCCS question bank includes detailed asthma exacerbation cases showing the transition from acute management to step-up controller therapy and discharge planning. You'll practice the full spectrum from emergency intubation to planning long-term ICS/LABA therapy.
Discharge Criteria & Safety
Ready for Discharge?
• Peak flow ≥70% predicted (or baseline if known) and improving
• SpO₂ ≥94-95% on room air
• Minimal/no accessory muscle use
• Able to speak in full sentences
• Ambulating safely
• On oral steroids (prednisone) and controller therapy
• Reliable follow-up arranged
Discharge Orders & Education
1. Medications:
◦ Continue prednisone taper (if on steroids at discharge): 40 mg daily × 3 days, 20 mg × 2 days, stop
◦ ICS inhaler with spacer (demonstrate technique—high-yield teaching point)
◦ ICS/LABA combination if indicated
◦ Albuterol inhaler PRN
2. Inhaler technique: Critical patient education
◦ Proper use of metered-dose inhaler (MDI)
◦ Use of spacer (increases lung deposition 2-3×)
◦ Rinse mouth after ICS (prevent oral thrush)
◦ Check technique at discharge
3. Asthma action plan: Written for home
◦ Green zone (controlled): No symptoms, peak flow >80% predicted
◦ Yellow zone (caution): Increased symptoms, peak flow 50-80%, start extra albuterol
◦ Red zone (danger): Severe dyspnea, peak flow <50%, go to ED immediately
4. Trigger avoidance:
◦ Dust, pets, mold, cockroaches (environmental remediation)
◦ Viral infections (hand hygiene)
◦ Exercise (warm-up, pre-exercise albuterol if needed)
◦ NSAIDS (aspirin-exacerbated asthma risk)
◦ Beta-blockers (contraindicated)
5. Smoking cessation: Referral to program; nicotine replacement
6. Follow-up: PCP within 1 week, pulmonology/allergy if recurrent exacerbations
Don't-Miss Diagnoses
When a patient presents with dyspnea and "asthma exacerbation":
• Anaphylaxis: Urticaria, angioedema, hypotension, rapid onset; give epinephrine IM (not albuterol)
• Pneumothorax: Acute unilateral chest pain, absent breath sounds; CXR, chest tube
• Foreign body: History of aspiration, unilateral findings
• Acute coronary syndrome: Chest pain, troponin, EKG (young asthmatics can have ACS)
• Pulmonary embolism: Pleuritic chest pain, unilateral leg swelling, D-dimer
• Acute epiglottitis: Stridor, drooling, inability to swallow (airway emergency)
• Anesthetic agents (NSAID, beta-blocker, ACE inhibitor): Iatrogenic triggers
Complete Order Set
Mild Exacerbation (Outpatient or Observation)
• Peak flow measurement (before and after albuterol)
• Pulse oximetry
• EKG (if chest pain, age >40, cardiopulmonary disease)
• Labs: CBC, CMP (if on chronic systemic steroids)
• Nebulized albuterol 2.5-5 mg q4-6h
• Oral prednisone 40-60 mg × 5 days
Moderate Exacerbation (ED/Admission)
• Continuous pulse oximetry + cardiac monitoring
• Peak flow (serial, after treatment)
• Labs: CBC, CMP, troponin (if chest pain), magnesium
• EKG
• CXR
• Nebulized albuterol 2.5-5 mg q20-30min
• IV or oral methylprednisolone 125 mg OR prednisone 40-60 mg
• Ipratropium 0.5 mg q4-6h (or DuoNeb with albuterol)
• IV access × 2
• Consider: Magnesium sulfate 2 g IV if inadequate response at 1-2 hours
Severe/Life-Threatening Exacerbation (ICU)
• All above, plus:
• Arterial blood gas (baseline and at 30-60 min)
• Continuous albuterol nebulizer 5-10 mg/hr
• Subcutaneous epinephrine 0.3-0.5 mg IM/SC q15-20min (if not responding to nebulizers)
• IV terbutaline 0.25 mg slow IV (reserved for ICU, monitor closely)
• Magnesium sulfate 2 g IV × 1-2 doses
• ICU admission; prepare for intubation
• Blood cultures, sputum culture if fever
• Infectious workup if suspected trigger
2-Minute Screen
Core asthma exacerbation principles in 120 seconds:
1. Classify severity: Mild (activity dyspnea), moderate (rest dyspnea, 25-30% RR, PF 50-80%), severe (1-word dyspnea, altered mental status, PF <50%)
2. Peak flow: Objective measure of severity; track response to therapy
3. Albuterol: Continuous nebulizer in severe cases; back-to-back in moderate
4. Steroids: Prednisone/methylprednisolone × 5-7 days, no prolonged taper
5. Magnesium: 2 g IV if not responding to initial albuterol/steroids after 1-2 hours
6. Intubation threshold: CO₂ >42 with acidosis, altered mental status, silent chest
7. Discharge: Peak flow ≥70% predicted, step-up controller (ICS, ICS/LABA), asthma action plan, inhaler technique
Related Articles
• CCS COPD Exacerbation: ABG Interpretation to Discharge
• CCS Acute Respiratory Failure: Intubation & Ventilator Management
• CCS Anaphylaxis: Recognition & Epinephrine Dosing
• CCS Chest X-Ray: Interpreting Common Findings
Ready to practice? The StudyCCS question bank includes 12+ asthma exacerbation cases—from mild outpatient cases to severe ICU intubations. Each case includes peak flow measurement, serial response tracking, and the exact moment when you need to escalate to magnesium sulfate or epinephrine. Real-time scoring highlights your decisions on albuterol dosing, steroid initiation, and discharge step-up therapy. Try a case today.